International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24
Authors
Keywords
Quality of life, Chronic myeloid leukemia, Questionnaire
Journal
QUALITY OF LIFE RESEARCH
Volume 23, Issue 3, Pages 825-836
Publisher
Springer Nature
Online
2013-09-12
DOI
10.1007/s11136-013-0523-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
- (2013) L. A. Williams et al. BLOOD
- Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
- (2013) F Efficace et al. LEUKEMIA
- Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
- (2012) Fabio Efficace et al. ANNALS OF HEMATOLOGY
- Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology
- (2012) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review
- (2012) Fabio Efficace et al. LEUKEMIA RESEARCH
- Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
- (2012) Kristin M. Phillips et al. SUPPORTIVE CARE IN CANCER
- Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire
- (2012) David Cella et al. VALUE IN HEALTH
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes
- (2011) F. Efficace et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
- (2011) Magnus Björkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
- (2011) Jorge Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease
- (2011) A. Hochhaus Hematology-American Society of Hematology Education Program
- Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia
- (2010) Javier Pinilla-Ibarz et al. CANCER
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started